Four months after restructuring the ailing Aegerion and axing about 80 staffers, CEO Mary Szela has completed the deal she wanted to bring in a late-stage asset.
Aegerion announced this morning that it will merge with Vancouver-based QLT, creating a new biotech named Novelion that leaves the QLT shareholders with the lion’s share of the stock and Szela with the helm.
An investment syndicate led by Deerfield is also stepping in to inject $22 million into the company through a share purchase agreement. And QLT’s investors will wind up with 67% of the shares of Novelion.
Shares of Aegerion shot up 42% on Wednesday morning.
Aegerion was afflicted by a variety of troubles. Ex-CEO Marc Beer ran into a hornet’s nest of regulatory issues, accused of making unsubstantiated claims about its drug Juxtapid. The drug, meanwhile, fell far short of expectations on the market, and Beer’s messy divorce added a few salacious allegations that helped set the stage for activist investor Alex Denner to push for a change.
That change became Szela, who had left Melinta earlier.
“A late-stage agent would be particularly impactful,” Szela told me earlier in the year as she sought to right a listing ship.
That asset materialized in QLT’s zuretinol (QLT091001) which the companies describe as a Phase III-ready orphan drug targeting inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes, spotlighting Leber Congenital Amaurosis and Retinitis Pigmentosa.
QLT, meanwhile, has experienced its own turmoil. The Canadian biotech has announced and called off two earlier mergers, including a recent pact with Auxilium.
Now Szela will see if she can make one good biotech out of two troubled companies, with its HQ in Canada and its operations in Cambridge, MA. It’s a sizable task.
By John Carroll
Source: Fierce Biotech
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
